Hannam and Partners Investor Report – Zelira completes enrolment in Diabetic Nerve Pain trial

H&P’s updated report on Zelira highlighted by the completed enrolment of participants in the diabetic nerve pain trial

Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Oludare Odumosu present a company update at the 2022 Annual General Meeting.

Zelira Global CEO Oludare Odumosu provides Proactive with an update on the company’s progress with its proprietary revenue-generating products, global expansion and its pipeline of candidates undergoing clinical development.

Hannam and Partners Investor Report – Zelira Therapeutics Oct 2022

Hannam and Partners Investor Report completed October 2022 provides an updated analysis of Zelira Therapeutics highlighting exciting, recently announced developments in their Rx and tech vertical

Hear the latest business updates from Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Dr Oludare Odumosu.

Hannam and Partners Investor Report – Zelira Therapeutics July 2022

Hannam and Partners investor report completed July 2022 provides and update and overview of Zelira Therapeutics following German regulatory approval and lists a target share price of $11.70

Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Dr Oludare Odumosu deliver a slide presentation and answer investor questions as part of a business update.

Zelira product helping young patient with autism spectrum disorder

Zelira AGM Presentation January 2022

CEO Oludare Odumosu and Chairman Osagie Imasogie presentation at the Zelira AGM 2022

Zelira AGM Presentation January 2022

A Global Biopharmaceutical Company Developing and Marketing Clinically Validated Cannabinoid-Based Medicines

  • 1
  • 2
  • 5

Start typing and press Enter to search

Shopping Cart